ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
17.40
-0.50 (-2.79%)
Dec 20, 2024, 4:00 PM EST - Market closed
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 21.25, with a low estimate of 14 and a high estimate of 26. The average target predicts an increase of 22.13% from the current stock price of 17.40.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +49.43% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +43.68% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +3.45% | Oct 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +14.94% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | +3.45% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
430.80M
from 258.22M
Increased by 66.84%
Revenue Next Year
494.22M
from 430.80M
Increased by 14.72%
EPS This Year
0.52
from -0.13
EPS Next Year
0.74
from 0.52
Increased by 41.95%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 451.6M | 535.5M | 779.4M | |||
| Avg | 430.8M | 494.2M | 635.7M | |||
| Low | 408.7M | 465.8M | 529.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 74.9% | 24.3% | 57.7% | |||
| Avg | 66.8% | 14.7% | 28.6% | |||
| Low | 58.3% | 8.1% | 7.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.58 | 0.92 | 1.29 | |||
| Avg | 0.52 | 0.74 | 1.00 | |||
| Low | 0.49 | 0.66 | 0.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 76.8% | 74.0% | |||
| Avg | - | 42.0% | 34.7% | |||
| Low | - | 25.6% | 10.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.